CAY-10603

CAS No. 1045792-66-2

CAY-10603( CAY10603 )

Catalog No. M10225 CAS No. 1045792-66-2

A highly potent and selective HDAC6 inhibitor with IC50 of 2 pM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 68 In Stock
5MG 87 In Stock
10MG 156 In Stock
25MG 291 In Stock
50MG 492 In Stock
100MG 709 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CAY-10603
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent and selective HDAC6 inhibitor with IC50 of 2 pM.
  • Description
    A highly potent and selective HDAC6 inhibitor with IC50 of 2 pM; 200-fold less potent for HDAC3 (IC50=0.42 nM) and no inhibition on HDAC1/2/8/10 (IC50> 100 nM); downregulates the levels of EGFR protein and synergizes with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines.(In Vitro):CAY10603 (Compound 7) shows potent inhibitory activities against pancreatic cancer cell lines, with IC50s of 1, 0.3, 0.1, 0.1, 0.6, <1, 0.5 μM for BxPC-3, HupT3, Mia Paca-2, Panc 04.03, SU.86.86, HMEC, HPDE6c7, respectively. CAY10603 (100 nM, 200-300 nM) is active against both the Mia Paca-2 and Panc04.03 cell lines. CAY10603 inhibits HDAC6 deacetylase activity, and supresses the proliferation of lung adenocarcinoma cells. CAY10603 also induces apoptosis of lung adenocarcinoma cells. Furthermore, CAY10603 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cell lines, partly through the destabilization of EGFR and inactivation of the EGFR pathway.
  • In Vitro
    CAY10603 (Compound 7) shows potent inhibitory activities against pancreatic cancer cell lines, with IC50s of 1, 0.3, 0.1, 0.1, 0.6, <1, 0.5 μM for BxPC-3, HupT3, Mia Paca-2, Panc 04.03, SU.86.86, HMEC, HPDE6c7, respectively. CAY10603 (100 nM, 200-300 nM) is active against both the Mia Paca-2 and Panc04.03 cell lines. CAY10603 inhibits HDAC6 deacetylase activity, and supresses the proliferation of lung adenocarcinoma cells. CAY10603 also induces apoptosis of lung adenocarcinoma cells. Furthermore, CAY10603 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cell lines, partly through the destabilization of EGFR and inactivation of the EGFR pathway.
  • In Vivo
    ——
  • Synonyms
    CAY10603
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC1|HDAC6
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1045792-66-2
  • Formula Weight
    446.4968
  • Molecular Formula
    C22H30N4O6
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(OC(C)(C)C)NC1=CC=C(C2=CC(C(NCCCCCCC(NO)=O)=O)=NO2)C=C1
  • Chemical Name
    Carbamic acid, N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]carbonyl]-5-isoxazolyl]phenyl]-, 1,1-dimethylethyl ester

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kozikowski AP, et al. J Med Chem. 2008 Aug 14;51(15):4370-3. 2. Wang Z, et al. Oncol Rep. 2016 Jul;36(1):589-97.
molnova catalog
related products
  • HNHA

    HNHA is an inhibitor of HDAC.

  • BRD4354

    BRD4354 is a moderately potent, selective, reversible inhibitor of HDAC5 and HDAC9 with IC50 of 0.85 uM and 1.88 uM.

  • 4-(1H-Pyrazol-4-yl)-...

    Detail unknown.